Cargando…
Central serous chorioretinopathy: Current update on management
Central serous chorioretinopathy (CSC), the fourth most common nonsurgical retinopathy with a usual self-limiting course, is known to present with persistent or recurrent form with distressing visual loss. Evolution of newer mutimodal imaging techniques have revolutionized the understanding about th...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219318/ https://www.ncbi.nlm.nih.gov/pubmed/30505108 http://dx.doi.org/10.4103/ojo.OJO_29_2018 |
_version_ | 1783368637236641792 |
---|---|
author | Manayath, George Joseph Ranjan, Ratnesh Karandikar, Smita S. Shah, Vanee Sheth Saravanan, Veerappan R. Narendran, Venkatapathy |
author_facet | Manayath, George Joseph Ranjan, Ratnesh Karandikar, Smita S. Shah, Vanee Sheth Saravanan, Veerappan R. Narendran, Venkatapathy |
author_sort | Manayath, George Joseph |
collection | PubMed |
description | Central serous chorioretinopathy (CSC), the fourth most common nonsurgical retinopathy with a usual self-limiting course, is known to present with persistent or recurrent form with distressing visual loss. Evolution of newer mutimodal imaging techniques have revolutionized the understanding about the pathophysiology of CSC, and hence the diagnosis and management. Multifactorial etiopathology of CSC promotes the use of multiple treatment modalities. With advances in investigative options, treatment options including conventional focal laser, micropulse laser, photodynamic therapy, and transpupillary thermotherapy are also advancing and refining. Medical management for CSC is also under evaluation with a wide spectrum of new drugs in vogue. However, standard of treatment is yet to be established through randomized clinical trials. This review article discusses the current approach to multimodal treatment options for CSC including conventional as well as newer therapeutic modalities. |
format | Online Article Text |
id | pubmed-6219318 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-62193182018-11-30 Central serous chorioretinopathy: Current update on management Manayath, George Joseph Ranjan, Ratnesh Karandikar, Smita S. Shah, Vanee Sheth Saravanan, Veerappan R. Narendran, Venkatapathy Oman J Ophthalmol Review Article Central serous chorioretinopathy (CSC), the fourth most common nonsurgical retinopathy with a usual self-limiting course, is known to present with persistent or recurrent form with distressing visual loss. Evolution of newer mutimodal imaging techniques have revolutionized the understanding about the pathophysiology of CSC, and hence the diagnosis and management. Multifactorial etiopathology of CSC promotes the use of multiple treatment modalities. With advances in investigative options, treatment options including conventional focal laser, micropulse laser, photodynamic therapy, and transpupillary thermotherapy are also advancing and refining. Medical management for CSC is also under evaluation with a wide spectrum of new drugs in vogue. However, standard of treatment is yet to be established through randomized clinical trials. This review article discusses the current approach to multimodal treatment options for CSC including conventional as well as newer therapeutic modalities. Medknow Publications & Media Pvt Ltd 2018 /pmc/articles/PMC6219318/ /pubmed/30505108 http://dx.doi.org/10.4103/ojo.OJO_29_2018 Text en Copyright: © 2018 Oman Ophthalmic Society http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Review Article Manayath, George Joseph Ranjan, Ratnesh Karandikar, Smita S. Shah, Vanee Sheth Saravanan, Veerappan R. Narendran, Venkatapathy Central serous chorioretinopathy: Current update on management |
title | Central serous chorioretinopathy: Current update on management |
title_full | Central serous chorioretinopathy: Current update on management |
title_fullStr | Central serous chorioretinopathy: Current update on management |
title_full_unstemmed | Central serous chorioretinopathy: Current update on management |
title_short | Central serous chorioretinopathy: Current update on management |
title_sort | central serous chorioretinopathy: current update on management |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219318/ https://www.ncbi.nlm.nih.gov/pubmed/30505108 http://dx.doi.org/10.4103/ojo.OJO_29_2018 |
work_keys_str_mv | AT manayathgeorgejoseph centralserouschorioretinopathycurrentupdateonmanagement AT ranjanratnesh centralserouschorioretinopathycurrentupdateonmanagement AT karandikarsmitas centralserouschorioretinopathycurrentupdateonmanagement AT shahvaneesheth centralserouschorioretinopathycurrentupdateonmanagement AT saravananveerappanr centralserouschorioretinopathycurrentupdateonmanagement AT narendranvenkatapathy centralserouschorioretinopathycurrentupdateonmanagement |